First human test for new peanut allergy drug begins
NCT ID NCT06331728
Summary
This was an early safety study to test a new drug called IGNX001 for peanut allergy. It involved 32 adults and older teenagers with confirmed peanut allergies. The main goal was to see if single, gradually increasing doses were safe and how the drug behaved in the body, not to treat the allergy itself.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
-
Monash Health, Sleep, Allergy, and Immunology
Clayton, Victoria, 3168, Australia
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
St Vincent's Sydney
Darlinghurst, New South Wales, 2010, Australia
Conditions
Explore the condition pages connected to this study.